FDA Approves, Leqembi, New Treatment for Early Alzheimer’s
The drug, Leqembi, may modestly slow cognitive decline in early [...]
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen
The report said the F.D.A.’s approval process for Aduhelm was [...]
What A.L.S. and Alzheimer’s Drug Approvals Have in Common
Regulators must balance patient’s needs with their safety.
Alzheimer’s Drug Slows Cognitive Decline in Key Study
Biogen and Eisai reported the finding from a large late-stage [...]
Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelm
The drug company will effectively give up on marketing Aduhelm, [...]
Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trials
Officials cited data showing the new Alzheimer’s drug has serious [...]
Inside a Campaign to Get Medicare Coverage for a New Alzheimer’s Drug
The Alzheimer’s Association has pushed relentlessly to get broad access [...]
F.D.A. Rushed a Drug for Preterm Births. Did It Put Speed Over Science?
The agency’s accelerated approval program for certain drugs has come [...]
Senate Confirms Califf as F.D.A. Chief in Tight Vote
The narrow 50-46 decision underscored the divisions on both sides [...]
Alzheimer’s Drug Aduhelm Faces Crucial Medicare Decision
Medicare officials are trying to determine whether to cover Aduhelm, [...]